ClinicalTrials.gg
CompletedNCT00624819Updated Jan 27, 2021Results posted

Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine

A Phase 3 interventional study of GSK1024805A and Prevenar in Infections, Streptococcal and Streptococcus Pneumoniae Vaccines, sponsored by GlaxoSmithKline. Completed at 6 sites in Poland. Open to participants aged 28 Months to 32 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-27.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
524
Allocation
Non-randomized
Ages
28 Months to 32 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing PHiD-CV vaccine in Streptococcal Infections — none open to participants now, none under way, none of them phase 3. PHiD-CV vaccine · Streptococcal Infections.

Enrollment
7th of 25
524 · median 360
Started
2008
with 3 others
Phase 3
24 of 25
none open now
Registered
6th of 25
by date
Lead sponsor
25 of 25
GlaxoSmithKline

Among the 25 studies testing PHiD-CV vaccine in Streptococcal Infections, this one is the 7th largest by enrollment, is one of 4 that started in 2008, is one of 24 in phase 3, and was the 6th registered.

Streptococcal Infections

147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.

Browse Streptococcal Infections studies →

Open to participants now

None of the 25 studies testing PHiD-CV vaccine in Streptococcal Infections is open now. The open studies under Streptococcal Infections, anywhere →

About PHiD-CV vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 28 Months to 32 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies testing PHiD-CV vaccine in Streptococcal Infections as a file.
02

Study summary

This protocol posting deals with objectives \& outcome measures of the extension phase up to 48-50 months post booster vaccination, to assess long-term antibody persistence in children at around 30, 42 and 66 months of age, who received previously 4 doses of pneumococcal conjugate vaccine. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = 00307554). This Protocol posting has been updated in order to comply with the FDA AA (Sep 2007).

Read the detailed description

This study consists in a serological follow-up study to evaluate persistence 12, 24 and 48 months after the booster vaccination study (107046). No study vaccines will be administered within this study.

03

Conditions studied

  • Infections, Streptococcal
  • Streptococcus Pneumoniae Vaccines

Keywords

  • Streptococcus pneumoniae
  • Haemophilus influenzae
  • Pneumococcal conjugate vaccine
  • Antibody persistence
04

Who can participate

Ages eligible
28 Months to 32 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between, and including, 28-30 months of age at the time of first blood sampling.
  • Subjects who previously participated in the 105553 and 107046 studies and who received a full four dose regimen of pneumococcal conjugate vaccine during the primary and booster studies.
  • Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • Written , covering visits 1, 2 and 3, obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Chronic administration of or other immune-modifying drugs within 6 months prior to the blood sampling
  • Administration of any additional pneumococcal vaccine since end of 107046 study.
  • Use of any or non-registered product (drug or vaccine) within 30 days preceding the blood sampling.
  • Administration of immunoglobulins and/or any blood products less than 6 months prior to blood sampling.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition since the end of the 107046 study, based on medical history and physical examination.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
524 participants (actual)

Study arms

  • Experimental
    Synflorix + Infanrix + Havrix and/or Varilrix Group

    This group consisted of subjects primed with Synflorix vaccine in the 10PN-PD-DIT-001 (1105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Synflorix vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose of Synflorix vaccine at 12-18 months of age co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix) and/or against varicella (a single dose of Varilrix).

    Biological: GSK1024805A · Biological: Infanrix hexa · Biological: Havrix · Biological: Varilrix

  • Active comparator
    Prevenar + Infanrix + Havrix and/or Varilrix Group

    This group consisted of subjects vaccinated with Prevenar vaccine in the 10PN-PD-DIT-001 (105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose at 12-18 months of age of Prevenar vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 111347 study, subjects had received at Month 48 (4 years post Dose 1 in study 105553) one dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).

    Biological: Prevenar · Biological: Infanrix hexa · Biological: Havrix · Biological: Varilrix

  • Experimental
    Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix

    This group consisted of subjects vaccinated with Prevenar and Synflorix vaccines in the 10PN-PD-DIT-001 (105553) and 10PN-PD-DIT-007 (107046) studies. In 105553 study, subjects had been primed with 3 doses Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In the 107046 study, subjects had received at 12-18 months of age a booster dose of Synflorix vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects had received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).

    Biological: GSK1024805A · Biological: Prevenar · Biological: Infanrix hexa · Biological: Havrix · Biological: Varilrix

  • Experimental
    Unprimed Group

    This group consisted of subjects between, and including, 64-68 months of age at the time of additional vaccination (primed subjects) or dose 1 (unprimed subjects), and for whom the investigator believed that their parents/guardians could and would comply with the requirements of the protocol. Subjects were not previously vaccinated with any pneumococcal vaccine and received 2 doses of Synflorix vaccine at 64-68 and 66-70 months of age (at Day 0 and Month 2). The Unprimed Group was added only in Year 4 of the study.

    Biological: GSK1024805A

Interventions

  • BiologicalGSK1024805A

    No vaccination in this trial

    Also known as: Synflorix

  • BiologicalPrevenar

    No vaccination in this trial

  • BiologicalInfanrix hexa

    No vaccination in this trial

  • BiologicalHavrix

    No vaccination in this trial

  • BiologicalVarilrix

    No vaccination in this trial

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations Greater Than or Equal to (≥) the Cut-off [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 microgram per milliliter (µg/mL) as seropositivity cut off.

    Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)

  2. Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations ≥ the Cut-off [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme -linked immunosorbent assay (ELISA), using 0.05 μg/mL as seropositivity cut off.

    Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)

  3. Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations ≥ the Cut-off [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 μg/mL as seropositivity cut off.

    Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)

Secondary outcomes

  1. Antibody Concentrations Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

    Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL).The seropositivity cut-off for the assay was ≥ 0.05 µg/mL.

    Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)

  2. Antibody Concentrations Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

    Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 µg/mL.

    Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)

  3. Antibody Concentrations Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

    Pneumococcal serotypes assessed were serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.

    Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PDDIT- 007)

  4. Antibody Concentrations Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

    Anti-pneumococcal serotypes assessed were serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F . Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.

    Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)

  5. Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

    Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

    Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)

  6. Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

    Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

    Time frame: At Year 2 (Y2) (post booster vaccination administrated in study 10PN-PD-DIT-007)

  7. Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

    Pneumococcal serotypes assessed were pneumococcal serotypes OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

    Time frame: At Year 4 (Y4) (post booster vaccination administrated in study 10PN-PD-DIT-007)

  8. Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

    Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

    Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)

  9. Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

    The seropositivity cut-off for the assay was ≥ 0.05 μg/mL. Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micrograms per milliliter (µg/mL).

    Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)

  10. Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) - Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)

    The seropositivity cut-off for the assay was ≥ 0.05 μg/mL. Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micrograms per milliliter (µg/mL).

    Time frame: At Year 2 (Y2) (post booster vaccination administrated in study 10PN-PDDIT- 007)

  11. Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

    Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.

    Time frame: At Year 4 (Y4) (post booster vaccination administrated in study 10PN-PD-DIT- 007)

  12. Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and 19A) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

    Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.

    Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)

  13. Opsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

    Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

    Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)

  14. Opsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

    Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

    Time frame: At Year 2 (Y2) (post booster vaccination administrated in study 10PN-PD-DIT-007)

  15. Opsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

    Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

    Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)

  16. Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

    Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

    Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)

  17. Antibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)

    Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.

    Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)

  18. Antibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)

    Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.

    Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT- 007)

  19. Antibody Concentrations to Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

    Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.

    Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT- 007)

  20. Antibody Concentrations to Protein D (Anti-PD) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

    Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.

    Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)

  21. Number of Subjects Reported With Solicited Local Symptoms

    Solicited local symptoms assessed were pain, redness and swelling. Any occurrence of symptom regardless of intensity grade. Any Redness or any Swelling symptom = any symptom greater than (\>) 0 millimeter (mm). Grade 3 pain = maximum intensity of local injection defined as subject crying when limb was moved/spontaneously painful. Grade 3 redness/swelling= maximum intensity of local injection \>30 mm. Follow-up period was of 4 days (Days 0-3) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 4 days for primed subjects and 2 periods of 4 days for unprimed subjects.

    Time frame: Within 4 days (Days 0-3) period(s) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study

  22. Number of Subjects Reported With Solicited General Symptoms

    Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (any fever defined as temperature by axillary measurement of 37.5°C and above). Grade 3 drowsiness was defined as drowsiness that prevented normal activity; Grade 3 irritability was defined as crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite was defined as subject not eating at all. Grade 3 fever was defined as axillary temperature \>39.5°C. Related AE was defined as any AE assessed by investigators to be causally related to administration of the study vaccine. Follow-up period was of 4 days (Days 0-3) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 4 days for primed subjects and 2 periods of 4 days for unprimed subjects.

    Time frame: Within 4 days (Days 0-3) period(s) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study

  23. Number of Subjects With Unsolicited Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. Follow-up period was of 31 days (Days 0-30) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 31 days for primed subjects and 2 periods of 31 days for unprimed subjects.

    Time frame: Within 31 days (Day 0-30) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study

  24. Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [Follow-up Period: Year 1 (111345 Sub-study)]

    An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" was defined an incidence of a SAE regardless of intensity/severity.

    Time frame: During Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007) i.e. for each primed subject: from the time the subject was enrolled in the 111345 study until he/she completed the same study (approximatively 12 months)

  25. Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [(Follow-up Period: Year 2 (111346 Sub-study) Until Year 4 (111347 Sub-study)]

    An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" is defined an incidence of a SAE regardless of intensity/severity.

    Time frame: From Year (Y) 2 to Y4 FU visit (post booster vaccination administered in 10PN-PD-DIT-007) i.e. for each subject(S): when S was enrolled in 111346 study until S completed the same study visit or the 111347 study visit (range of 1 to 3 years for each S))

  26. Number of Subjects With Serious Adverse Events (SAEs) [Follow-up Period: Vaccination Period in Year 4 (111347 Sub-study)]

    An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" is defined an incidence of a SAE regardless of intensity/severity.

    Time frame: For primed groups: from Months 48-49 (additional vaccination period); for unprimed group: from Day 0 up to Month 3 (catch-up vaccination period)

  27. Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.

    Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)

  28. Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.

    Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)

  29. Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.

    Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)

  30. Number of Seropositive Subjects for Opsophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Analysis was performed with Unprimed group included. The seropositivity cut-off for the assay was 8.

    Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)

  31. Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The results for the immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.

    Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)

  32. Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibation ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.

    Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)

  33. Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.

    Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)

  34. Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.

    Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)

  35. Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were mesured by Opsonophagocytic activity (OPA). The seropositivity cut-off for the assay was 8.

    Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)

  36. Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic activity (OPA). The seropositivity cut-off for the assay was 8.

    Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)

  37. Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic Activity (OPA). The seropositivity cut-off for the assay was 8.

    Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)

  38. Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic Activity (OPA). The seropositivity cut-off for the assay was 8.

    Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)

  39. Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

    A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.

    Time frame: At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)

  40. Number of Seropositive Subjects for Anti Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 2 (111345 Sub-study)]

    A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.

    Time frame: At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)

  41. Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

    A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.

    Time frame: At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)

  42. Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.

    Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)

  43. Number of Seropositive Subjects for Anti-vaccine Pneumococcal Serotypes Antibodies [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

    A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 microgram per milliliter (µg/mL) as seropositivity cut off.

    Time frame: For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)

07

Results

Posted Mar 18, 2020

Participant flow

Primed groups included Synflorix vaccinated subjects in study 10PN-PD-DIT-007. The Unprimed Group, added only in Year 4,included subjects unprimed with any pneumococcal vaccine age-matched with primed groups. The study included 3 sub-studies (111345, 111346, 111347) corresponding to Year 1, 2 and 4 time points post Dose 1 in Study 10PN-PD-DIT-001.

Follow-up Period: Year 1
Participant flow — Follow-up Period: Year 1
MilestoneSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Started391311020
Completed391311020
Not completed0000
Follow-up Period: Year 2
Participant flow — Follow-up Period: Year 2
MilestoneSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Started37031960
Completed37031960
Not completed0000
Follow-up Period: Year 4
Participant flow — Follow-up Period: Year 4
MilestoneSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Started2642065100
Completed2631964100
Not completed1110
Withdrew: Parents decision0010
Withdrew: Lost to follow-up1100

Outcome measures

PrimaryNumber of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations Greater Than or Equal to (≥) the Cut-off [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 microgram per milliliter (µg/mL) as seropositivity cut off.

Time frame:
At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations Greater Than or Equal to (≥) the Cut-off [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 antibodies, Y1372799
Anti-4 antibodies, Y138431102
Anti-5 antibodies, Y138619101
Anti-6B antibodies, Y138431100
Anti-7F antibodies, Y138717102
Anti-9V antibodies, Y138817102
Anti-14 antibodies, Y138731102
Anti-18C antibodies, Y138431102
Anti-19F antibodies, Y138731102
Anti-23F antibodies, Y138631102
PrimaryNumber of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations ≥ the Cut-off [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme -linked immunosorbent assay (ELISA), using 0.05 μg/mL as seropositivity cut off.

Time frame:
At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations ≥ the Cut-off [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 antibodies, Y23541890
Anti-4 antibodies, Y23563096
Anti-5 antibodies, Y23622195
Anti-6B antibodies, Y23553095
Anti-7F antibodies, Y23671995
Anti-9V antibodies, Y23623096
Anti-14 antibodies, Y23673096
Anti-18C antibodies, Y23653096
Anti-19F antibodies, Y23683095
Anti-23F antibodies, Y23573095
PrimaryNumber of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations ≥ the Cut-off [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 μg/mL as seropositivity cut off.

Time frame:
At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations ≥ the Cut-off [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 antibodies, Y42381471
Anti-4 antibodies, Y42381872
Anti-5 antibodies, Y42571973
Anti-6B antibodies, Y42581974
Anti-7F antibodies, Y42601373
Anti-9V antibodies, Y42551975
Anti-14 antibodies, Y42631975
Anti-18C antibodies, Y42561973
Anti-19F antibodies, Y42601975
Anti-23F antibodies, Y42541974
SecondaryAntibody Concentrations Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL).The seropositivity cut-off for the assay was ≥ 0.05 µg/mL.

Time frame:
At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Geometric mean · µg/mL
Antibody Concentrations Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
µg/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 antibodies, Y10.29 (0.27 to 0.32)0.04 (0.03 to 0.06)0.26 (0.21 to 0.31)
Anti-4 antibodies, Y10.5 (0.45 to 0.55)0.59 (0.46 to 0.75)1.01 (0.84 to 1.21)
Anti-5 antibodies, Y10.59 (0.54 to 0.65)0.07 (0.05 to 0.11)0.42 (0.35 to 0.52)
Anti-6B antibodies, Y10.52 (0.45 to 0.6)0.98 (0.63 to 1.53)0.54 (0.42 to 0.69)
Anti-7F antibodies, Y10.71 (0.66 to 0.77)0.08 (0.05 to 0.13)0.83 (0.7 to 0.99)
Anti-9V antibodies, Y10.79 (0.71 to 0.89)0.93 (0.7 to 1.22)0.58 (0.49 to 0.68)
Anti-14 antibodies, Y11.27 (1.12 to 1.44)1.79 (1.29 to 2.48)1.47 (1.17 to 1.85)
Anti-18C antibodies, Y10.88 (0.81 to 0.96)0.91 (0.71 to 1.16)0.82 (0.69 to 0.98)
Anti-19F antibodies, Y11.43 (1.27 to 1.6)0.83 (0.47 to 1.45)1.51 (1.19 to 1.92)
Anti-23F antibodies, Y10.61 (0.54 to 0.69)1.18 (0.84 to 1.68)0.7 (0.56 to 0.88)
SecondaryAntibody Concentrations Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 µg/mL.

Time frame:
At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Geometric mean · µg/mL
Antibody Concentrations Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
µg/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 antibodies, Y20.19 (0.17 to 0.21)0.07 (0.05 to 0.1)0.17 (0.14 to 0.2)
Anti-4 antibodies, Y20.27 (0.24 to 0.3)0.3 (0.24 to 0.38)0.52 (0.43 to 0.64)
Anti-5 antibodies, Y20.41 (0.37 to 0.45)0.09 (0.06 to 0.13)0.33 (0.27 to 0.41)
Anti-6B antibodies, Y20.7 (0.58 to 0.83)0.99 (0.57 to 1.71)0.9 (0.63 to 1.29)
Anti-7F antibodies, Y20.53 (0.48 to 0.58)0.1 (0.06 to 0.16)0.59 (0.49 to 0.71)
Anti-9V antibodies, Y20.64 (0.54 to 0.75)0.61 (0.37 to 1)0.5 (0.37 to 0.68)
Anti-14 antibodies, Y21.73 (1.48 to 2.02)1.94 (1.12 to 3.36)1.7 (1.25 to 2.31)
Anti-18C antibodies, Y20.54 (0.48 to 0.62)0.59 (0.39 to 0.88)0.48 (0.38 to 0.59)
Anti-19F antibodies, Y22.16 (1.77 to 2.65)0.99 (0.51 to 1.91)2.41 (1.67 to 3.46)
Anti-23F antibodies, Y20.68 (0.56 to 0.82)1.24 (0.83 to 1.85)0.64 (0.48 to 0.86)
SecondaryAntibody Concentrations Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

Pneumococcal serotypes assessed were serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.

Time frame:
At Year 4 (Y4) (post booster vaccination administered in study 10PN-PDDIT- 007)
Reported as:
Geometric mean · μg/mL
Antibody Concentrations Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
μg/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 antibodies, Y40.2 (0.17 to 0.24)0.17 (0.07 to 0.43)0.23 (0.17 to 0.32)
Anti-4 antibodies, Y40.19 (0.16 to 0.22)0.23 (0.12 to 0.41)0.31 (0.25 to 0.38)
Anti-5 antibodies, Y40.36 (0.31 to 0.4)0.19 (0.1 to 0.35)0.35 (0.28 to 0.43)
Anti-6B antibodies, Y41.3 (1.1 to 1.55)1.19 (0.68 to 2.07)0.97 (0.74 to 1.27)
Anti-7F antibodies, Y40.44 (0.38 to 0.52)0.16 (0.08 to 0.36)0.49 (0.37 to 0.65)
Anti-9V antibodies, Y41.17 (0.92 to 1.47)1.19 (0.43 to 3.27)0.67 (0.46 to 0.99)
Anti-14 antibodies, Y43.66 (3.01 to 4.45)2.57 (1.22 to 5.42)2.94 (2.11 to 4.12)
Anti-18C antibodies, Y40.7 (0.58 to 0.84)0.87 (0.4 to 1.88)0.63 (0.45 to 0.89)
Anti-19F antibodies, Y44.17 (3.4 to 5.1)4.74 (2.24 to 10)4.05 (3.03 to 5.41)
Anti-23F antibodies, Y41.57 (1.26 to 1.96)1.64 (1.15 to 2.34)1.12 (0.79 to 1.58)
SecondaryAntibody Concentrations Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

Anti-pneumococcal serotypes assessed were serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F . Antibody concentrations against pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.

Time frame:
For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Reported as:
Geometric mean · μg/mL
Antibody Concentrations Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
μg/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Anti-1 antibodies, PRE———0.1 (0.08 to 0.13)
Anti-1 antibodies, D75.36 (4.54 to 6.33)3.04 (1.22 to 7.56)5 (3.72 to 6.71)1.35 (1.08 to 1.69)
Anti-1 antibodies, M3———2.39 (2.06 to 2.78)
Anti-4 antibodies, PRE———0.04 (0.03 to 0.05)
Anti-4 antibodies, D712.11 (10.08 to 14.54)10.45 (6.49 to 16.81)7.13 (5.18 to 9.82)4.74 (3.77 to 5.95)
Anti-4 antibodies, M3———7.32 (6.7 to 8)
Anti-5 antibodies, PRE———0.1 (0.08 to 0.12)
Anti-5 antibodies, D76.23 (5.19 to 7.49)3.24 (1.44 to 7.29)8.15 (5.71 to 11.63)1.2 (0.97 to 1.49)
Anti-5 antibodies, M3———3.1 (2.7 to 3.55)
Anti-6B antibodies, PRE———0.21 (0.15 to 0.29)
Anti-6B antibodies, D73.68 (3.16 to 4.29)2.85 (1.89 to 4.3)2.15 (1.62 to 2.85)0.53 (0.4 to 0.71)
Anti-6B antibodies, M3———1.25 (1.01 to 1.54)
Anti-7F antibodies, PRE———0.12 (0.09 to 0.16)
Anti-7F antibodies, D77.16 (6.11 to 8.39)3.26 (1.67 to 6.35)7.57 (5.84 to 9.81)1.67 (1.33 to 2.09)
Anti-7F antibodies, M3———4.55 (3.93 to 5.26)
Anti-9V antibodies, PRE———0.19 (0.12 to 0.28)
Anti-9V antibodies, D79.94 (8.59 to 11.51)9 (5.49 to 14.77)5.32 (4.08 to 6.94)0.9 (0.66 to 1.23)
Anti-9V antibodies, M3———2.2 (1.85 to 2.62)
Anti-14 antibodies, PRE———0.58 (0.38 to 0.87)
Anti-14 antibodies, D719.38 (16.74 to 22.43)13.26 (6.91 to 25.43)18.61 (14.23 to 24.34)1.72 (1.2 to 2.46)
Anti-14 antibodies, M3———7.81 (6.34 to 9.63)
Anti-18C antibodies, PRE———0.1 (0.07 to 0.15)
Anti-18C antibodies, D715.51 (13.06 to 18.43)19.71 (11.87 to 32.74)13.34 (9.34 to 19.05)2.26 (1.66 to 3.09)
Anti-18C antibodies, M3———13.21 (11.44 to 15.25)
Anti-19F antibodies, PRE———0.6 (0.4 to 0.89)
Anti-19F antibodies, D711.63 (10 to 13.51)16.44 (10.68 to 25.29)8.09 (6.29 to 10.42)5.12 (3.97 to 6.62)
Anti-19F antibodies, M3———15.47 (13.08 to 18.29)
Anti-23F antibodies, PRE———0.1 (0.07 to 0.14)
Anti-23F antibodies, D76.5 (5.61 to 7.53)9.34 (5.62 to 15.54)4.7 (3.43 to 6.45)0.42 (0.3 to 0.59)
Anti-23F antibodies, M3———1.63 (1.32 to 2.01)
SecondaryOpsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

Time frame:
At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Geometric mean · Titer
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
TiterSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 OPA Titers, Y116.2 (13.8 to 19)4.8 (3.6 to 6.4)7.3 (5.9 to 9)
Anti-4 OPA Titers, Y159.8 (45.7 to 78.3)192.9 (82.4 to 452)88.9 (54.6 to 144.6)
Anti-5 OPA Titers, Y124.2 (20.8 to 28.2)5.1 (3.6 to 7.4)11.2 (8.7 to 14.3)
Anti-6B OPA Titers, Y135.5 (26.5 to 47.5)476.9 (175.3 to 1298)44.7 (24 to 83.3)
Anti-7F OPA Titers, Y11855.7 (1644.4 to 2094.1)350.4 (121.8 to 1008)1617.2 (1152.9 to 2268.3)
Anti-9V OPA Titers, Y1791.5 (701.8 to 892.8)1240.7 (829.4 to 1855.9)370.5 (281.8 to 487.2)
Anti-14 OPA Titers, Y1551.9 (486.5 to 626.2)607.3 (385.3 to 957.1)456.6 (361.1 to 577.3)
Anti-18C OPA Titers, Y123.5 (18.6 to 29.8)15.5 (6.1 to 39.2)10.4 (7.1 to 15.4)
Anti-19F OPA Titers, Y153.4 (44.7 to 63.9)35.4 (15.9 to 78.6)58 (41.6 to 80.7)
Anti-23F OPA Titers, Y1784.9 (625.4 to 985)3013.1 (1349.5 to 6727.2)552.3 (362.1 to 842.5)
SecondaryOpsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

Time frame:
At Year 2 (Y2) (post booster vaccination administrated in study 10PN-PD-DIT-007)
Reported as:
Geometric mean · Titer
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
TiterSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 OPA Titers, Y28.4 (7.3 to 9.7)4 (4 to 4)6.3 (4.9 to 8)
Anti-4 OPA Titers, Y229 (22.1 to 38)33.5 (11.9 to 94.6)39.3 (23.7 to 65.2)
Anti-5 OPA Titers, Y211.4 (10 to 13)4.3 (3.9 to 4.7)7.4 (6 to 9.1)
Anti-6B OPA Titers, Y2167.2 (124.1 to 225.2)526.1 (210.5 to 1314.4)213.7 (117.8 to 387.6)
Anti-7F OPA Titers, Y21488.7 (1358.3 to 1631.6)1068.3 (619.5 to 1842.4)1387.8 (1096.2 to 1756.9)
Anti-9V OPA Titers, Y2648.5 (570 to 737.7)730.4 (457.7 to 1165.7)391 (279.2 to 547.5)
Anti-14 OPA Titers, Y2660.2 (567.2 to 768.4)651 (348.6 to 1215.5)534.4 (381.6 to 748.4)
Anti-18C OPA Titers, Y234.9 (26.6 to 45.7)34.8 (11.7 to 103.2)17.7 (10.7 to 29.2)
Anti-19F OPA Titers, Y278.1 (60.9 to 100.2)49.2 (21.2 to 113.9)105.4 (65.8 to 168.7)
Anti-23F OPA Titers, Y2632 (483 to 827)1923 (952.2 to 3883.7)435 (250.5 to 755.5)
SecondaryOpsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

Pneumococcal serotypes assessed were pneumococcal serotypes OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

Time frame:
At Year 4 (Y4) (post booster vaccination administrated in study 10PN-PD-DIT-007)
Reported as:
Geometric mean · Titer
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
TiterSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 OPA Titers, Y48.8 (7.1 to 10.9)4.6 (3.4 to 6.4)8.9 (5.9 to 13.2)
Anti-4 OPA Titers, Y437.9 (27.2 to 52.8)62.2 (13.6 to 284.7)50.7 (26.5 to 97)
Anti-5 OPA Titers, Y47.7 (6.8 to 8.9)5.3 (3.5 to 8.1)5.5 (4.5 to 6.6)
Anti-6B OPA Titers, Y4875.7 (658.7 to 1164.3)978.3 (395.3 to 2421.3)716.4 (417.4 to 1229.7)
Anti-7F OPA Titers, Y41693.1 (1489.3 to 1924.8)965.8 (666.8 to 1398.9)1602.1 (1286.9 to 1994.5)
Anti-9V OPA Titers, Y4747.4 (624.9 to 894.1)563.8 (220.2 to 1444)558.6 (403 to 774.2)
Anti-14 OPA Titers, Y41139.8 (961.9 to 1350.5)687.9 (267.8 to 1767.4)849.4 (645.4 to 1117.8)
Anti-18C OPA Titers, Y446.4 (33.3 to 64.5)35.3 (8.8 to 142.5)26.6 (14.3 to 49.3)
Anti-19F OPA Titers, Y4151.7 (115.9 to 198.4)178.8 (64.6 to 495.1)129.3 (83.1 to 201.4)
Anti-23F OPA Titers, Y41518.4 (1107.9 to 2080.9)3366.1 (1599.2 to 7085.1)1146.2 (596.8 to 2201.3)
SecondaryOpsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

Pneumococcal serotypes assessed were OPA-1, OPA-4, OPA-5, OPA-6B, OPA-7F, OPA-9V, OPA-14, OPA-18C, OPA-19F and OPA-23F. The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

Time frame:
For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Reported as:
Geometric mean · Titers
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
TitersSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Anti-1 OPA Titers, PRE———5 (4.2 to 5.9)
Anti-1 OPA Titers, D72920.8 (2353.5 to 3624.7)1331 (586.7 to 3019.5)1816.1 (1090 to 3025.8)605 (462.7 to 791.2)
Anti-1 OPA Titers, M3———128.3 (97.3 to 169.1)
Anti-4 OPA Titers, PRE———11.5 (7.2 to 18.3)
Anti-4 OPA Titers, D723633.7 (19118.5 to 29215.3)10650.3 (3969.2 to 28577.6)8592.8 (5609.3 to 13163.1)18262.1 (15571.6 to 21417.4)
Anti-4 OPA Titers, M3———4451.3 (3962.4 to 5000.6)
Anti-5 OPA Titers, PRE———4.9 (4.3 to 5.7)
Anti-5 OPA Titers, D7822.3 (662.7 to 1020.3)375.6 (217.4 to 648.9)683.6 (428.6 to 1090.2)295.6 (219.4 to 398.3)
Anti-5 OPA Titers, M3———93.2 (73.7 to 117.8)
Anti-6B OPA Titers, PRE———70.7 (33.5 to 149.2)
Anti-6B OPA Titers, D73513.1 (2858.1 to 4318.1)3566.6 (2446.1 to 5200.3)1590.5 (942.8 to 2683.3)1971.4 (1238 to 3139.2)
Anti-6B OPA Titers, M3———2536.9 (2014.1 to 3195.5)
Anti-7F OPA Titers, PRE———1368.2 (849.6 to 2185.8)
Anti-7F OPA Titers, D725196.4 (21149.5 to 30017.6)17828.8 (10270.4 to 30949.7)13098.6 (9715.5 to 17659.8)19243.4 (15701.4 to 23584.5)
Anti-7F OPA Titers, M3———9692 (8299.3 to 11318.4)
Anti-9V OPA Titers, PRE———398.2 (253.8 to 624.9)
Anti-9V OPA Titers, D79419.4 (7586 to 11695.9)12234.7 (8280.5 to 18077.3)7730.3 (5361.8 to 11145.2)8322.7 (6605.7 to 10486.1)
Anti-9V OPA Titers, M3———6456.1 (5458.1 to 7636.6)
Anti-14 OPA Titers, PRE———586.5 (439 to 783.6)
Anti-14 OPA Titers, D78572.3 (7145.4 to 10284.3)4192.8 (2218.6 to 7923.7)6883.1 (5057.3 to 9368)4678.2 (3788 to 5777.5)
Anti-14 OPA Titers, M3———4891.1 (4178.8 to 5724.8)
Anti-18C OPA Titers, PRE———5.3 (4.2 to 6.6)
Anti-18C OPA Titers, D73378.9 (2652.2 to 4304.8)3478.6 (1788.5 to 6765.8)1663.2 (970.5 to 2850.2)2503.1 (1692.6 to 3701.6)
Anti-18C OPA Titers, M3———2255.9 (1876.9 to 2711.4)
Anti-19F OPA Titers, PRE———12 (8.3 to 17.5)
Anti-19F OPA Titers, D71346.4 (1068.6 to 1696.5)2340.4 (654.8 to 8365.2)662.3 (430 to 1020.1)700.2 (456.1 to 1074.9)
Anti-19F OPA Titers, M3———1437.7 (1146.9 to 1802.3)
Anti-23F OPA Titers, PRE———176.4 (83.4 to 373.2)
Anti-23F OPA Titers, D78700.4 (7021.7 to 10780.5)11341.1 (5374.6 to 23931)7871.9 (4965.3 to 12480.1)6813.9 (5249.5 to 8844.6)
Anti-23F OPA Titers, M3———5586.1 (4666.1 to 6687.5)
SecondaryAntibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

The seropositivity cut-off for the assay was ≥ 0.05 μg/mL. Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micrograms per milliliter (µg/mL).

Time frame:
At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Geometric mean · μg/mL
Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
μg/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A antibodies, Y10.28 (0.24 to 0.32)0.44 (0.28 to 0.7)0.27 (0.21 to 0.36)
Anti-19A antibodies, Y10.28 (0.25 to 0.32)0.21 (0.13 to 0.33)0.23 (0.17 to 0.3)
SecondaryAntibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) - Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)

The seropositivity cut-off for the assay was ≥ 0.05 μg/mL. Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micrograms per milliliter (µg/mL).

Time frame:
At Year 2 (Y2) (post booster vaccination administrated in study 10PN-PDDIT- 007)
Reported as:
Geometric mean · μg/mL
Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) - Follow-Up Period: Persistence Analysis in Year 2 (111346 Sub-study)
μg/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A antibodies, Y20.33 (0.28 to 0.4)0.57 (0.3 to 1.11)0.4 (0.27 to 0.58)
Anti-19A antibodies, Y20.37 (0.31 to 0.44)0.25 (0.14 to 0.44)0.35 (0.25 to 0.5)
SecondaryAntibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.

Time frame:
At Year 4 (Y4) (post booster vaccination administrated in study 10PN-PD-DIT- 007)
Reported as:
Geometric mean · μg/mL
Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and - 19A) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
μg/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A antibodies, Y40.92 (0.77 to 1.1)0.69 (0.34 to 1.38)0.75 (0.55 to 1.03)
Anti-19A antibodies, Y41.3 (1.07 to 1.59)1.08 (0.5 to 2.33)1.14 (0.77 to 1.68)
SecondaryAntibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and 19A) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

Antibody concentrations against 6A and 19A pneumococcal serotypes were determined as Geometric Mean Antibody Concentrations (GMC) and expressed as micro grams per milliliter (µg/mL). The seropositivity cut-off for the assay was ≥ 0.05 μg/mL.

Time frame:
For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Reported as:
Geometric mean · μg/mL
Antibody Concentrations Against Cross-reactive Pneumococcal Serotypes 6A and 19A (Anti-6A and 19A) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
μg/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Anti-6A antibodies, PRE———0.2 (0.15 to 0.27)
Anti-6A antibodies, D72.2 (1.85 to 2.6)1.67 (1 to 2.8)1.33 (0.96 to 1.83)0.44 (0.33 to 0.58)
Anti-6A antibodies, M3———0.92 (0.73 to 1.16)
Anti-19A antibodies, PRE———0.44 (0.32 to 0.6)
Anti-19A antibodies, D72.79 (2.33 to 3.35)2.44 (1.2 to 4.96)1.72 (1.14 to 2.61)1.1 (0.84 to 1.45)
Anti-19A antibodies, M3———2.39 (1.9 to 3.01)
SecondaryOpsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

Time frame:
At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Geometric mean · Titers
Opsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
TitersSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A OPA Titers, Y159 (45.9 to 76)610.2 (317.7 to 1171.9)46.6 (28.3 to 76.8)
Anti-19A OPA Titers, Y16 (5.2 to 6.8)5.9 (3.7 to 9.5)5.5 (4.5 to 6.8)
SecondaryOpsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

Time frame:
At Year 2 (Y2) (post booster vaccination administrated in study 10PN-PD-DIT-007)
Reported as:
Geometric mean · Titers
Opsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
TitersSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A OPA Titers, Y2121.8 (95.2 to 156)356.5 (134.6 to 944.6)133.7 (81.8 to 218.7)
Anti-19A OPA Titers, Y212.8 (10.4 to 15.7)10.9 (5.2 to 22.8)11.1 (7.6 to 16.2)
SecondaryOpsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

Time frame:
At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Geometric mean · Titers
Opsonophagocytic Activity (OPA) Titers Against Crossreactive Pneumococcal Serotypes 6A and 19 A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
TitersSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A OPA Titers, Y4213.5 (165.4 to 275.7)227.8 (72.1 to 720)153.5 (90.5 to 260.2)
Anti-19A OPA Titers, Y431.2 (23.6 to 41.3)14.3 (5.6 to 36.8)21.8 (13.3 to 35.7)
SecondaryOpsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

Opsonophagocytic activity were assessed for pneumococcal serotypes 6A and 19A (OPA-6A and OPA-19A). The seropositivity cut-off for the assay was ≥ 8. Opsonophagocytic activity was expressed as Geometric Mean Antibody Titers (GMT).

Time frame:
For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Reported as:
Geometric mean · Titers
Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
TitersSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Anti-6A OPA Titers, PRE———102.6 (61.5 to 171.2)
Anti-6A OPA Titers, D71217.7 (957.8 to 1548.2)1490.2 (681.6 to 3257.8)467.7 (293.8 to 744.5)826.5 (593.9 to 1150.2)
Anti-6A OPA Titers, M3———943.4 (691.3 to 1287.4)
Anti-19A OPA Titers, PRE———9.9 (7 to 13.8)
Anti-19A OPA Titers, D7467 (335 to 651.1)437.6 (81.3 to 2356.3)106.1 (54.1 to 208.3)431.2 (269.4 to 689.9)
Anti-19A OPA Titers, M3———376.4 (256.3 to 552.6)
SecondaryAntibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)

Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.

Time frame:
At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Geometric mean · EL.U/mL
Antibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)
EL.U/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Antibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)822.1 (731.5 to 923.9)93.9 (66.6 to 132.3)193.6 (155.9 to 240.4)
SecondaryAntibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)

Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.

Time frame:
At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT- 007)
Reported as:
Geometric mean · EL.U/mL
Antibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)
EL.U/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Antibody Concentrations to Protein D (Anti-PD) - Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)573.2 (509.6 to 644.8)116.7 (80.9 to 168.3)157.5 (128.7 to 192.8)
SecondaryAntibody Concentrations to Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.

Time frame:
At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT- 007)
Reported as:
Geometric mean · EL.U/mL
Antibody Concentrations to Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
EL.U/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Antibody Concentrations to Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]372.4 (329.6 to 420.9)144.9 (86.3 to 243.2)161.4 (128.4 to 203)
SecondaryAntibody Concentrations to Protein D (Anti-PD) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

Anti-protein D (Anti-PD) antibody concentrations by Enzyme-Linked Immunosorbent Assay (ELISA) were calculated, expressed as geometric mean concentrations (GMCs) in ELISA unit per milli-liter (EL.U/mL) and tabulated. The seropositivity cut-off for the assay was ≥ 100 EL.U/mL.

Time frame:
For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Reported as:
Geometric mean · EL.U/mL
Antibody Concentrations to Protein D (Anti-PD) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
EL.U/mLSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Anti-PD antibodies, PRE———106 (91.1 to 123.4)
Anti-PD antibodies, D72106 (1806.7 to 2454.9)718.2 (442.5 to 1165.7)680.7 (522.9 to 886.2)382.9 (320.7 to 457.2)
Anti-PD antibodies, M3———708.6 (604.6 to 830.4)
SecondaryNumber of Subjects Reported With Solicited Local Symptoms

Solicited local symptoms assessed were pain, redness and swelling. Any occurrence of symptom regardless of intensity grade. Any Redness or any Swelling symptom = any symptom greater than (\>) 0 millimeter (mm). Grade 3 pain = maximum intensity of local injection defined as subject crying when limb was moved/spontaneously painful. Grade 3 redness/swelling= maximum intensity of local injection \>30 mm. Follow-up period was of 4 days (Days 0-3) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 4 days for primed subjects and 2 periods of 4 days for unprimed subjects.

Time frame:
Within 4 days (Days 0-3) period(s) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study
Reported as:
Count of participants · Participants
Number of Subjects Reported With Solicited Local Symptoms
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Pain, Any15793454
Redness, Any9051421
Swelling, Any6741520
Pain, Grade 37153
Redness, Grade 3 (> 30 mm)7001
Swelling, Grade 3 (> 30 mm)5012
SecondaryNumber of Subjects Reported With Solicited General Symptoms

Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (any fever defined as temperature by axillary measurement of 37.5°C and above). Grade 3 drowsiness was defined as drowsiness that prevented normal activity; Grade 3 irritability was defined as crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite was defined as subject not eating at all. Grade 3 fever was defined as axillary temperature \>39.5°C. Related AE was defined as any AE assessed by investigators to be causally related to administration of the study vaccine. Follow-up period was of 4 days (Days 0-3) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 4 days for primed subjects and 2 periods of 4 days for unprimed subjects.

Time frame:
Within 4 days (Days 0-3) period(s) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study
Reported as:
Count of participants · Participants
Number of Subjects Reported With Solicited General Symptoms
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Drowsiness, Any4921212
Drowsiness, Grade 31000
Drowsiness, Related4821111
Irritability, Any35468
Irritability, Related35468
Irritability, Grade 30000
Loss of appetite, Any303613
Loss of appetite, Grade 31010
Loss of appetite, Related303511
Fever, Any13025
Fever, >39,5°C0000
Fever, Related13015
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination. Follow-up period was of 31 days (Days 0-30) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study, thus one period of 31 days for primed subjects and 2 periods of 31 days for unprimed subjects.

Time frame:
Within 31 days (Day 0-30) after Synflorix vaccination in Year 4 Persistence and Immunological Memory 111347 Study
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events (AEs)
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Number of Subjects With Unsolicited Adverse Events (AEs)25036
SecondaryNumber of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [Follow-up Period: Year 1 (111345 Sub-study)]

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" was defined an incidence of a SAE regardless of intensity/severity.

Time frame:
During Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007) i.e. for each primed subject: from the time the subject was enrolled in the 111345 study until he/she completed the same study (approximatively 12 months)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [Follow-up Period: Year 1 (111345 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [Follow-up Period: Year 1 (111345 Sub-study)]100
SecondaryNumber of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [(Follow-up Period: Year 2 (111346 Sub-study) Until Year 4 (111347 Sub-study)]

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" is defined an incidence of a SAE regardless of intensity/severity.

Time frame:
From Year (Y) 2 to Y4 FU visit (post booster vaccination administered in 10PN-PD-DIT-007) i.e. for each subject(S): when S was enrolled in 111346 study until S completed the same study visit or the 111347 study visit (range of 1 to 3 years for each S))
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [(Follow-up Period: Year 2 (111346 Sub-study) Until Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Number of Subjects With Serious Adverse Events (SAEs) Related to Study Procedures [(Follow-up Period: Year 2 (111346 Sub-study) Until Year 4 (111347 Sub-study)]000
SecondaryNumber of Subjects With Serious Adverse Events (SAEs) [Follow-up Period: Vaccination Period in Year 4 (111347 Sub-study)]

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. "Any" is defined an incidence of a SAE regardless of intensity/severity.

Time frame:
For primed groups: from Months 48-49 (additional vaccination period); for unprimed group: from Day 0 up to Month 3 (catch-up vaccination period)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs) [Follow-up Period: Vaccination Period in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Number of Subjects With Serious Adverse Events (SAEs) [Follow-up Period: Vaccination Period in Year 4 (111347 Sub-study)]0000
SecondaryNumber of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.

Time frame:
At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 OPA, Y1188226
Anti-4 OPA, Y12012165
Anti-5 OPA, Y1241246
Anti-6B OPA, Y11642344
Anti-7F OPA, Y13432085
Anti-9V OPA, Y13512690
Anti-14 OPA, Y13362589
Anti-18C OPA, Y11731025
Anti-19F OPA, Y13061983
Anti-23F OPA, Y13012682
SecondaryNumber of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.

Time frame:
At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 OPA, Y292015
Anti-4 OPA, Y21461248
Anti-5 OPA, Y2169231
Anti-6B OPA, Y22412467
Anti-7F OPA Titers, Y23502690
Anti-9V OPA, Y23472787
Anti-14 OPA, Y23332485
Anti-18C OPA, Y21651129
Anti-19F OPA, Y22792178
Anti-23F OPA, Y22852572
SecondaryNumber of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. The seropositivity cut-off for the assay was 8.

Time frame:
At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-1 OPA, Y455117
Anti-4 OPA, Y4107833
Anti-5 OPA, Y480211
Anti-6B OPA, Y42231562
Anti-7F OPA, Y42481571
Anti-9V OPA, Y42421468
Anti-14 OPA, Y42471470
Anti-18C OPA, Y4121827
Anti-19F OPA, Y42111462
Anti-23F OPA, Y42091555
SecondaryNumber of Seropositive Subjects for Opsophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Analysis was performed with Unprimed group included. The seropositivity cut-off for the assay was 8.

Time frame:
For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Opsophagocytic Activity Against Pneumococcal Serotypes [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Anti-1 OPA, PRE———8
Anti-1 OPA, D7193134890
Anti-1 OPA, M3———87
Anti-4 OPA, PRE———17
Anti-4 OPA, D7194135093
Anti-4 OPA, M3———94
Anti-5 OPA, PRE———8
Anti-5 OPA, D7186134787
Anti-5 OPA, M3———89
Anti-6B OPA, PRE———35
Anti-6B OPA, D7196134884
Anti-6B OPA, M3———94
Anti-7F OPA, PRE———67
Anti-7F OPA, D7199135093
Anti-7F OPA, M3———93
Anti-9V OPA, PRE———75
Anti-9V OPA, D7201135193
Anti-9V OPA, M3———94
Anti-14 OPA, PRE———81
Anti-14 OPA, D7197135194
Anti-14 OPA, M3———95
Anti-18C OPA, PRE———7
Anti-18C OPA, D7190134888
Anti-18C OPA, M3———92
Anti-19F OPA, PRE———30
Anti-19F OPA, D7194135091
Anti-19F OPA, M3———93
Anti-23F OPA, PRE———47
Anti-23F OPA, D7197134995
Anti-23F OPA, M3———95
SecondaryNumber of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The results for the immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.

Time frame:
At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A antibodies, Y13763197
Anti-19A antibodies, Y13662993
SecondaryNumber of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibation ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.

Time frame:
At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A antibodies, Y23303086
Anti-19A antibodies, Y23192583
SecondaryNumber of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.

Time frame:
At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A antibodies, Y42561872
Anti-19A antibodies, Y42601874
SecondaryNumber of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by 22F-inhibition ELISA. The seropositivity cut-off for the assay was 0.05 μg/mL.

Time frame:
For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Anti-6A antibodies, PRE———76
Anti-6A antibodies, D7208145492
Anti-6A antibodies, M3———97
Anti-19A antibodies, PRE———88
Anti-19A antibodies, D7208145497
Anti-19A antibodies, M3———98
SecondaryNumber of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were mesured by Opsonophagocytic activity (OPA). The seropositivity cut-off for the assay was 8.

Time frame:
At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A OPA, Y11962445
Anti-19A OPA, Y145310
SecondaryNumber of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic activity (OPA). The seropositivity cut-off for the assay was 8.

Time frame:
At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 2 (111346 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A OPA, Y22352162
Anti-19A OPA, Y2115829
SecondaryNumber of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic Activity (OPA). The seropositivity cut-off for the assay was 8.

Time frame:
At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Anti-6A OPA Titers, Y41941251
Anti-19A OPA Titers, Y4135734
SecondaryNumber of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Pneumococcal serotypes assessed were 6A and 19A. The immune responses were measured by Opsonophagocytic Activity (OPA). The seropositivity cut-off for the assay was 8.

Time frame:
For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Opsonophagocytic Activity Against Pneumococcal Cross-reactive Serotypes 6A and 19A [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Anti-6A OPA, PRE———57
Anti-6A OPA, D7185124688
Anti-6A OPA, M3———87
Anti-19A OPA, PRE———25
Anti-19A OPA, D7173113681
Anti-19A OPA, M3———87
SecondaryNumber of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]

A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.

Time frame:
At Year 1 (Y1) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 1 (111345 Sub-study)]3731171
SecondaryNumber of Seropositive Subjects for Anti Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 2 (111345 Sub-study)]

A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.

Time frame:
At Year 2 (Y2) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 2 (111345 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Number of Seropositive Subjects for Anti Protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 2 (111345 Sub-study)]3401565
SecondaryNumber of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]

A seropositive subject was a subject whose anti-PD antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.

Time frame:
At Year 4 (Y4) (post booster vaccination administered in study 10PN-PD-DIT-007)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or Varilrix
Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Persistence Analysis in Year 4 (111347 Sub-study)]2411254
SecondaryNumber of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. The seropositivity cut-off for the assay was 100 EL.U/ML.

Time frame:
For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-protein D (Anti-PD) [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Anti-PD antibodies, PRE———54
Anti-PD antibodies, D7207145492
Anti-PD antibodies, M3———98
SecondaryNumber of Seropositive Subjects for Anti-vaccine Pneumococcal Serotypes Antibodies [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]

A seropositive subject was a subject whose antibody concentration was greater than or equal to (≥) the cut-off value. Analysis was performed using the 22F-inhibition Enzyme-linked immunosorbent assay (ELISA), using 0.05 microgram per milliliter (µg/mL) as seropositivity cut off.

Time frame:
For primed groups: At Month 48+7 days after additional dose (D7);For unprimed group: at Day 0 (D0) (Pre-vaccination [PRE]), at Day 7 (D7) post dose 1 (of the 2-dose catch-up vaccination) and at Month 3 (M3) post dose 2 (of the 2-dose catch-up vaccination)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-vaccine Pneumococcal Serotypes Antibodies [Follow-up Period: Immunogenicity Analysis in Year 4 (111347 Sub-study)]
ParticipantsSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
Anti-1 antibodies, PRE———69
Anti-1 antibodies, D7207145497
Anti-1 antibodies, M3———98
Anti-4 antibodies, PRE———29
Anti-4 antibodies, D7208145498
Anti-4 antibodies, M3———98
Anti-5 antibodies, PRE———72
Anti-5 antibodies, D7207145498
Anti-5 antibodies, M3———98
Anti-6B antibodies, PRE———77
Anti-6B antibodies, D7207145494
Anti-6B antibodies, M3———98
Anti-7F antibodies, PRE———64
Anti-7F antibodies, D7208145498
Anti-7F antibodies, M3———98
Anti-9V antibodies, PRE———67
Anti-9V antibodies, D7208145494
Anti-9V antibodies, M3———98
Anti-14 antibodies, PRE———90
Anti-14 antibodies, D7208145497
Anti-14 antibodies, M3———98
Anti-18C antibodies, PRE———52
Anti-18C antibodies, D7207145497
Anti-18C antibodies, M3———98
Anti-19F antibodies, PRE———75
Anti-19F antibodies, D7208145497
Anti-19F antibodies, M3———98
Anti-23F antibodies, PRE———54
Anti-23F antibodies, D7208145490
Anti-23F antibodies, M3———98

Adverse events

Collected over Solicited and Unsolicited AEs were collected within 4 days and 31 days post-Synflorix vaccination, respectively, for subjects participating to Year 4 follow-up period. SAEs related to study procedure were collected at Year 1 in sub-study 111345 and from Year 2 up to Year 4 follow-up period in sub-studies 111346-111347 for primed subjects. Any SAEs were collected during the vaccination period in the111347 study (i.e. from Month 48-49 for primed subjects and from Month 0-3 for unprimed subjects).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Synflorix + Infanrix + Havrix and/or Varilrix Group0/391 (0%)1/391 (0.3%)188/264 (71.2%)
Prevenar + Infanrix + Havrix and/or Varilrix Group0/31 (0%)0/31 (0%)12/20 (60%)
Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix0/102 (0%)0/102 (0%)39/65 (60%)
Unprimed Group0/100 (0%)0/100 (0%)65/100 (65%)
Most frequent serious events
Most frequent serious events
EventSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
BroncopneumoniaInfections and infestations1/3910/310/1020/100
Most frequent other events
Most frequent other events
EventSynflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed Group
PainGeneral disorders157/2649/2034/6454/100
RednessGeneral disorders90/2645/2014/6421/100
SwellingGeneral disorders67/2644/2015/6420/100
IrritabilityGeneral disorders35/2634/206/648/100
DrowsinessGeneral disorders49/2632/2012/6412/100
Loss of appetiteGeneral disorders30/2633/206/6413/100
Fever (Axillary temperature ≥ 37.5°C)General disorders13/2630/202/645/100

Baseline characteristics

The demographic characteristics are presented separately for each Follow-up Period (Year 1, 2 and 4).

Age, Continuous
Age, Continuous(Months)Synflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed GroupTotal
Mean29.1 ± 0.8829.0 ± 0.7529.1 ± 0.81—29.1 ± 0.86
Age, Continuous
Age, Continuous(Months)Synflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed GroupTotal
Mean41.1 ± 1.0441.1 ± 1.0941.2 ± 1.04—41.1 ± 1.04
Age, Continuous
Age, Continuous(Months)Synflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed GroupTotal
Mean67.4 ± 0.8467.1 ± 0.9767.3 ± 0.8965.4 ± 1.3166.9 ± 1.28
Sex: Female, Male
Sex: Female, Male(Participants)Synflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed GroupTotal
Female2031452—269
Male1881750—255
Sex: Female, Male
Sex: Female, Male(Participants)Synflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed GroupTotal
Female1921450—256
Male1781746—241
Sex: Female, Male
Sex: Female, Male(Participants)Synflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed GroupTotal
Female139103553237
Male125103047212
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Synflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed GroupTotal
White - caucasia/ european heritage386311020519
White arabic/ north african heritage40408
Other, not specified10001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Synflorix + Infanrix + Havrix and/or Varilrix GroupPrevenar + Infanrix + Havrix and/or Varilrix GroupPrevenar + Synflorix + Infanrix + Havrix and/or VarilrixUnprimed GroupTotal
White - Caucasian / European heritage36531960492
White - Arabic / North African heritage40004
Other, not specified10001

1 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • GSK Investigational Site
    Bydgoszcz, 85-021, Poland
  • GSK Investigational Site
    Debica, 39-200, Poland
  • GSK Investigational Site
    Krakow, 31-503, Poland
  • GSK Investigational Site
    Olesnica, 56-400, Poland
  • GSK Investigational Site
    Poznan, 61-709, Poland
  • GSK Investigational Site
    Siemianowice Slaskie, 41-103, Poland
09

References and documents

Individual participant data

Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2008 to primary completion in Jun 2008, 2 months.

Results were first posted in Mar 2020, 11 years 9 months after primary completion. A results delay was requested in Jul 2012.

Of 28 industry-sponsored phase 3 interventional studies under Streptococcal Infections, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 13. This study's 2 months is below that.

Counting every sponsor, half of 29 studies reached it within 10 months; a quarter within 8 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2008
First posted
Feb 27, 2008
StartActual
Mar 3, 2008
Primary completionActual
Jun 2, 2008
CompletionActual
Jun 2, 2008
Results delay requested
Jul 24, 2012
Results first posted
Mar 18, 2020
Last update
Jan 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00624819
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 27, 2008
Start date
Mar 3, 2008
Primary completion
Jun 2, 2008
Completion
Jun 2, 2008
Results posted
Mar 18, 2020
Last update
Jan 27, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PHiD-CV vaccine · Heptavalent Pneumococcal Conjugate Vaccine · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Chickenpox Vaccine

Start the discussion